Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights
November 8, 2022 4:02 PM ESTAchieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to dateAuthorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 17 years in U.S., EU, Japan, and additional markets Announced data about our prototype's broad immune response against circulating variants when used as a booster Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of ageRefining full year 2022 total revenue... More
